All News
Researchers have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.
Dr. Marco Mielcarek will collaborate with researchers across three institutions to improve preventative care for graft-vs.-host disease.
Congratulations to those who made the 2026 Seattle Met’s annual list of the best health care professionals in the region.
Recent research shows that the same mechanisms that aggressive prostate cancer cells manipulate to elude therapy can be used against them, forcing them to shapeshift back into their more treatable form.
She has received a prestigious American Society of Clinical Oncology Career Development Award for work on a new biomarker for triple-negative breast cancer.
Dr. Mohamed Sorror has received funding to lead three parallel, multicenter, pragmatic randomized trials involving approximately 800 adults aged 60 and older at 18 AML centers across the United States.